CD28null and Regulatory T Cells Are Substantially Disrupted in Patients with End-Stage Renal Disease Due to Diabetes Mellitus.
Adult
CD28 Antigens
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Diabetes Complications
/ genetics
Diabetes Mellitus
/ genetics
Female
Flow Cytometry
Humans
Kidney Failure, Chronic
/ etiology
Killer Cells, Natural
/ immunology
Male
Middle Aged
Renal Dialysis
T-Lymphocytes, Regulatory
/ immunology
CD28null cells
diabetes mellitus
end-stage renal disease
lymphocytes
regulatory T cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Mar 2021
15 Mar 2021
Historique:
received:
12
02
2021
revised:
05
03
2021
accepted:
12
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
1
5
2021
Statut:
epublish
Résumé
End-stage renal disease (ESRD) is associated with alterations in T-cell immunity, including increased CD28null and reduced regulatory T cells (Tregs). However, whether immune disturbances are due to ESRD or primary disease is not yet clear. As diabetes mellitus is the leading cause of ESRD, we evaluated its impact on the immune profile of ESRD patients. CD28null, Tregs, and natural killer cells were initially analyzed by flow cytometry in 30 predialysis ESRD patients due to diabetes (DM), 30 non-DM (NDM), and 25 healthy controls. Measurements were repeated after 6 months on hemodialysis (HD) or peritoneal dialysis (CAPD). The percentage of CD4 + CD28null cells, CD8 + CD28null cells, and Tregs showed significant differences in DM, NDM, and controls; mean rank 33.71 vs. 25.68 vs. 18.88, Diabetes mellitus affects T-cell subtypes even at predialysis stage, though changes become more prominent after commencement on HD.
Sections du résumé
BACKGROUND
BACKGROUND
End-stage renal disease (ESRD) is associated with alterations in T-cell immunity, including increased CD28null and reduced regulatory T cells (Tregs). However, whether immune disturbances are due to ESRD or primary disease is not yet clear. As diabetes mellitus is the leading cause of ESRD, we evaluated its impact on the immune profile of ESRD patients.
METHODS
METHODS
CD28null, Tregs, and natural killer cells were initially analyzed by flow cytometry in 30 predialysis ESRD patients due to diabetes (DM), 30 non-DM (NDM), and 25 healthy controls. Measurements were repeated after 6 months on hemodialysis (HD) or peritoneal dialysis (CAPD).
RESULTS
RESULTS
The percentage of CD4 + CD28null cells, CD8 + CD28null cells, and Tregs showed significant differences in DM, NDM, and controls; mean rank 33.71 vs. 25.68 vs. 18.88,
CONCLUSIONS
CONCLUSIONS
Diabetes mellitus affects T-cell subtypes even at predialysis stage, though changes become more prominent after commencement on HD.
Identifiants
pubmed: 33804135
pii: ijms22062975
doi: 10.3390/ijms22062975
pmc: PMC8001943
pii:
doi:
Substances chimiques
CD28 Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Hum Immunol. 2019 Sep;80(9):748-754
pubmed: 30853362
PLoS One. 2015 Apr 10;10(4):e0122198
pubmed: 25860138
BMC Nephrol. 2019 Aug 5;20(1):301
pubmed: 31383007
Adv Exp Med Biol. 2019;1165:3-15
pubmed: 31399958
Clin Immunol. 2021 Apr;225:108685
pubmed: 33549833
J Mol Endocrinol. 2016 Feb;56(2):R33-54
pubmed: 26576641
J Diabetes Res. 2014;2014:394206
pubmed: 25587544
Clin Immunol. 2006 Jan;118(1):83-91
pubmed: 16257266
J Clin Rheumatol. 2012 Jun;18(4):212-6
pubmed: 22647859
Clin Immunol. 2020 Jun;215:108423
pubmed: 32304735
Nat Rev Nephrol. 2013 May;9(5):255-65
pubmed: 23507826
Front Immunol. 2021 Jan 15;11:585819
pubmed: 33519807
Biosci Rep. 2019 Oct 30;39(10):
pubmed: 31427482
Curr Urol Rep. 2015 Jan;16(1):471
pubmed: 25404185
Clin Nephrol. 2021 Jan;95(1):37-44
pubmed: 33074093
Hum Immunol. 2013 Jan;74(1):6-13
pubmed: 22902395
Toxins (Basel). 2020 Jul 05;12(7):
pubmed: 32635646
Am J Nephrol. 2019;50(2):115-125
pubmed: 31238306
Cytokine. 2000 Sep;12(9):1385-90
pubmed: 10975999
Am J Kidney Dis. 2017 May;69(5):667-674
pubmed: 28049555
Lancet. 2001 Jun 2;357(9270):1777-89
pubmed: 11403834
Pediatr Diabetes. 2017 Dec;18(8):785-793
pubmed: 28102614
Adv Exp Med Biol. 2017;1003:3-14
pubmed: 28667551
Am J Reprod Immunol. 2018 Mar;79(3):
pubmed: 29315988
Mol Immunol. 2019 Aug;112:233-239
pubmed: 31181422
Cent Eur J Immunol. 2020;45(1):29-36
pubmed: 32425677
J Am Soc Nephrol. 2006 Oct;17(10):2731-41
pubmed: 16988067
Curr Pharm Des. 2013;19(32):5695-703
pubmed: 23448484
Nephrol Dial Transplant. 2020 Apr 1;35(4):624-632
pubmed: 30202981
Am J Kidney Dis. 2006 Nov;48(5):752-60
pubmed: 17059994
Cell Metab. 2013 Jan 8;17(1):20-33
pubmed: 23312281
Clin Sci (Lond). 2017 Jul 31;131(16):2183-2199
pubmed: 28760771
Biomed Pharmacother. 2018 Dec;108:656-662
pubmed: 30245465
Kidney Int. 2019 Jun;95(6):1418-1432
pubmed: 30982673
Nephrology (Carlton). 2016 Feb;21(2):81-5
pubmed: 26461175
Nephrology (Carlton). 2021 Feb;26(2):185-196
pubmed: 32935413